期刊文献+

血液系统疾病的肝脏表现 被引量:1

Hepatic manifestations of hematological diseases
原文传递
导出
摘要 多种血液系统疾病可累及肝脏,并导致复杂多样的临床表现,如高非结合型胆红素血症、单克隆性免疫球蛋白升高、门静脉或肝静脉血栓形成/门静脉高压、肝脾肿大及肝脏铁沉积等临床表现。现简要论述常见溶血性疾病、凝血和抗凝因子缺陷、骨髓增殖性肿瘤、噬血细胞综合征、多发性骨髓瘤、白血病、淋巴瘤等血液系统疾病的肝脏表现,以帮助临床医生更好诊治此类疾病。 Liver involvement is often observed in hematological disorders,resulting in liver abnormality,including unconjugated hyperbilirubinemia,monoclonal hyperglobulinemia,portal vein,or hepatic vein thrombosis or portal hypertension,hepatosplenomegaly,or iron accumulation in the liver.Here we summarize the major hematological diseases that often affect the liver:hemolytic anemia,defect in coagulation or anti-coagulation factors,myeloproliferative neoplasm,hemophagocytic lymphohistiocytosis,multiple myeloma,leukemia,and lymphoma.We hope this review will help clinicians diagnose and manage the patients with liver involvement by hematological disorders.
作者 单姗 赵新颜 贾继东 Shan Shan;Zhao Xinyan;Jia Jidong(Liver Research Center,Beijing Friendship Hospital,Capital Medical University Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis&National Clinical Research Center for Digestive Diseases,Beijing 100050,China)
出处 《中华肝脏病杂志》 CSCD 北大核心 2022年第4期347-351,共5页 Chinese Journal of Hepatology
基金 国家自然科学基金(82000569)。
关键词 血液病 肝脏疾病 肝脏表现 Hematopathy Liver disease Liver manifestation
  • 相关文献

参考文献3

二级参考文献32

  • 1Swerdlow SH, Campo E, Harris NL, et al. World Health Organi- zation Classification of Tumours of Haematopoietie and Lymphoid Tissue [ M ]. 4th ed. Lyon:IARC Press, 2008:194-195.
  • 2Owen RG, Treon SP, A1-Katib A, et al. Clinicopathological definition of Waldenslrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia [J]. Semin Oncol, 2003, 30(2): 110-115.
  • 3Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstr6m' s maeroglobulinemia [J]. N Engl J Med, 2012, 367 ( 9 ) :826-833.
  • 4Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia[J]. Blood, 2009, 113 ( 18 ): 4163-4170.
  • 5Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom' s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH) [J]. Leuk Res, 2010, 34 ( 10): 1340-1343.
  • 6Kastritis E, Zervas K, Repoussis P, et al. Prognostication inyoung and old patients with Waldenstr6m's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase [J]. Clin Lymphoma Myeloma, 2009, 9( 1 ): 50-52.
  • 7Treon SP. How I treat Waldenstr6m macroglobulinemia [J]. Blood, 2009, 114(12): 2375-2385.
  • 8Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreat- ed Waldenstr6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma [J]. J Clin Oncol, 2013, 31 (3): 301-307.
  • 9Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstr6m macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98) [J]. Leuk Lymphoma, 2004, 45 (10): 2047- 2055.
  • 10Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobu- linemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group [J]. J Clin Oncol, 2007, 25(12): 1570-1575.

共引文献136

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部